This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: International Journal of Neuropsychopharmacology 14:991-996 (2011)
Authors: Y Levkovitz, L Rabany, E.V Harel, A Zangen
Levkovitz, Y., Rabany, L., Harel, E. V., & Zangen, A. (2011). The International Journal of Neuropsychopharmacology, 14(07), 991-996.
This study examined the effect of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) H-coil stimulation on schizophrenic patients. In the study, patients were given 20 daily Deep Transcranial Magnetic Stimulation sessions over the prefrontal cortex. The study demonstrated that brain stimulation using the H-coil significantly alleviates the negative symptoms of schizophrenia as well as enhancing cognition.